The partnership includes support for the design of the Phase III trial and assistance in securing external funding.

Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma – – Rademikibart reduced annualized exacerbations in patients with ...

Your belly is growing, and so is your baby. Use this interactive pregnancy timeline tool to track your baby's development week by week – from conception to delivery – and learn what to expect ...

Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former ...

med.unc.edu Objective We aimed to determine whether mepolizumab, an anti-IL-5 antibody, was more effective than placebo for improving dysphagia symptoms and decreasing oesophageal eosinophil counts in ...

†Present address: Department of Biotechnology and Biosciences, University of Milan-Bicocca, 20126 Milan, Italy. Article Views are the COUNTER-compliant sum of full text article downloads since ...

Itepekimab is a fully human monoclonal antibody that binds to and inhibits interleukin-33 (IL33), an initiator and amplifier of broad inflammation in COPD. IL33 is thought to be involved in different ...

yahoo.com Background It has been claimed that exhaled nitric oxide (FeNO) could be regarded as a surrogate marker for sputum eosinophil count in patients with asthma. However, the FeNO threshold value ...

To the best of our knowledge, this is the first study to identify IL-5RA expressed on eosinophils of the GI tract in IBD compared to that in EGID and DGBI. The present study demonstrates a potential ...

The phase 3 MATINEE trial (NCT04133909) provided additional context for where mepolizumab may be most useful. 2 This trial randomized 804 patients with a history of frequent exacerbations and ...